J.L. Merlin

468 total citations
22 papers, 299 citations indexed

About

J.L. Merlin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J.L. Merlin has authored 22 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J.L. Merlin's work include Colorectal Cancer Treatments and Studies (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and RNA Interference and Gene Delivery (3 papers). J.L. Merlin is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and RNA Interference and Gene Delivery (3 papers). J.L. Merlin collaborates with scholars based in France, United States and Netherlands. J.L. Merlin's co-authors include Stéphane Marchal, A. Guerci, Francis Witz, Carsten Rose, L Feldmann, Philippe Bécuwe, Muriel Barberi‐Heyob, Jean-François Mirjolet, A. Sapin and Philippe Maincent and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

J.L. Merlin

20 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.L. Merlin France 9 179 149 63 33 30 22 299
G.J. Schuurhuis Netherlands 11 289 1.6× 230 1.5× 146 2.3× 35 1.1× 14 0.5× 18 489
Victoria Ling Australia 6 140 0.8× 143 1.0× 28 0.4× 14 0.4× 35 1.2× 12 270
Jana Gump United States 7 195 1.1× 300 2.0× 55 0.9× 14 0.4× 33 1.1× 14 419
Susan Wittig Germany 13 120 0.7× 235 1.6× 58 0.9× 34 1.0× 28 0.9× 25 387
Julie Turzanski United Kingdom 11 173 1.0× 145 1.0× 119 1.9× 39 1.2× 28 0.9× 15 342
Marsha Jones United States 9 60 0.3× 164 1.1× 46 0.7× 29 0.9× 15 0.5× 11 349
Daniel Nguyen United States 10 91 0.5× 146 1.0× 52 0.8× 53 1.6× 65 2.2× 22 326
D-C Zhou France 10 187 1.0× 155 1.0× 99 1.6× 53 1.6× 19 0.6× 11 284
Muriel Duluc France 6 147 0.8× 102 0.7× 22 0.3× 11 0.3× 40 1.3× 11 225
Martin Grundy United Kingdom 14 154 0.9× 240 1.6× 238 3.8× 45 1.4× 25 0.8× 26 442

Countries citing papers authored by J.L. Merlin

Since Specialization
Citations

This map shows the geographic impact of J.L. Merlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.L. Merlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.L. Merlin more than expected).

Fields of papers citing papers by J.L. Merlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.L. Merlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.L. Merlin. The network helps show where J.L. Merlin may publish in the future.

Co-authorship network of co-authors of J.L. Merlin

This figure shows the co-authorship network connecting the top 25 collaborators of J.L. Merlin. A scholar is included among the top collaborators of J.L. Merlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.L. Merlin. J.L. Merlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Husson, Marie, et al.. (2021). 35P Increased sensitivity to olaparib by BRCA1/2 knockdown using a CRISPR/Cas9-mediated knock-in method in pancreatic cancer cell lines. Annals of Oncology. 32. S1356–S1356. 1 indexed citations
2.
Mirjolet, Céline, J.L. Merlin, G. Truc, et al.. (2019). RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study. EBioMedicine. 41. 420–426. 15 indexed citations
3.
Lièvre, Astrid, J.L. Merlin, Pierre Laurent‐Puig, et al.. (2015). 420 Flash RAS study: RAS testing assessment in patients with metastatic colorectal cancer in 2014. European Journal of Cancer. 51. S85–S85.
4.
Lièvre, Astrid, Pascal Artru, Pierre Laurent‐Puig, et al.. (2013). The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011. European Journal of Cancer. 49(9). 2126–2133. 16 indexed citations
5.
6.
Milano, G., J-M Ferrero, Fabienne Thomas, et al.. (2013). Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine. Cancer Research. 73(24_Supplement). P3–15. 4 indexed citations
7.
Sapin, A., et al.. (2010). Photochemical internalization for pDNA transfection: Evaluation of poly(d,l-lactide-co-glycolide) and poly(ethylenimine) nanoparticles. International Journal of Pharmaceutics. 403(1-2). 276–284. 13 indexed citations
8.
Chrétien, Anne-Sophie, et al.. (2009). P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Therapy. 16(6). 498–507. 20 indexed citations
9.
Sapin, A., et al.. (2009). Optimization of a New Non-viral Vector for Transfection: Eudragit Nanoparticles for the Delivery of a DNA Plasmid. Technology in Cancer Research & Treatment. 8(6). 433–443. 25 indexed citations
10.
Merlin, J.L., Géraldine Perkins, Astrid Lièvre, et al.. (2008). Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer (CRC). Journal of Clinical Oncology. 26(15_suppl). 4126–4126. 5 indexed citations
11.
Chrétien, Anne-Sophie, et al.. (2008). P53 potentiates PTEN-mediated inhibition of EGFR downstream signaling pathway by cetuximab in prostate cancer cells. European Journal of Cancer Supplements. 6(9). 146–146. 2 indexed citations
12.
Dolivet, Gilles, Anders Høgset, Patrick Erbacher, et al.. (2005). Eradication of p53-mutated head and neck squamous cell carcinoma (HNSCC) xenografts using nonviral p53 gene therapy and photochemical internalisation (PCI). Journal of Clinical Oncology. 23(16_suppl). 3155–3155. 1 indexed citations
13.
Calvet, Loreley, Alexandre Santos, A. Valent, et al.. (2004). No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. British Journal of Cancer. 91(6). 1205–1212. 13 indexed citations
14.
Merlin, J.L., et al.. (2003). Meiotic Structures in the Animal-Parasitic Nematode Ascaris megalocephala: Synaptonemal Complexes, Recombination Nodules, and Centrioles.. PubMed. 35(2). 223–7. 1 indexed citations
15.
Mirjolet, Jean-François, et al.. (2002). G1/S but not G0/G1 cell fraction is related to 5‐fluorouracil cytotoxicity. Cytometry. 48(1). 6–13. 28 indexed citations
16.
17.
Barberi‐Heyob, Muriel, et al.. (1995). [Stability of 5-fluorouracil solutions according to different parameters].. PubMed. 82(12). 1025–31. 7 indexed citations
18.
19.
20.
Merlin, J.L., et al.. (1993). Intraperitoneal injection of dipyridamole increases the life span of tumor bearing mice treated with fluorouracil.. PubMed. 6(5). 535–40. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.J. Schuurhuis Breakdown of academic impact, for papers by Victoria Ling Breakdown of academic impact, for papers by Jana Gump Breakdown of academic impact, for papers by Susan Wittig Breakdown of academic impact, for papers by Julie Turzanski Breakdown of academic impact, for papers by Marsha Jones Breakdown of academic impact, for papers by Daniel Nguyen Breakdown of academic impact, for papers by D-C Zhou Breakdown of academic impact, for papers by Muriel Duluc Breakdown of academic impact, for papers by Martin Grundy
Rankless by CCL
2026